University Hospital, Lille is recruiting patients for a PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma.
The trial, designated NCT04400539, aims to enroll up to 20 participants at 1 sites.
About the Study
Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma
Treatment Approach
This trial uses a combination of checkpoint inhibitors that was FDA-approved for mesothelioma in 2020.
Key trial details:
- Phase: PHASE2
- Sponsor: University Hospital, Lille
- Enrollment target: 20
- Status: RECRUITING
Why This Trial Matters
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening